More: American College of Rheumatology (ACR) 71st Annual Meeting

ACR 2007: Advances in Arthritis and Related Conditions CME

January 23 - 23, 2008, Boston, Massachusetts

Author Information and Disclosures

This activity is not sanctioned by, nor a part of, the American College of Rheumatology.

Release Date: January 14, 2008; Valid for credit through January 14, 2009

Credits Available
Physicians - maximum of 1.5 AMA PRA Category 1 Credit(s)™ for physicians

The content of this CME activity, "ACR 2007: Advances in Arthritis and Related Conditions" was developed by the faculty.

To participate in this activity: 1) review the target audience, learning objectives and author disclosures, 2) study the education content 3) answer the posttest and evaluation 4) view/print certificate View details

Legal Disclaimer

The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.

The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the American College of Rheumatology. These materials and the related activity are not sanctioned by the American College of Rheumatology or the commercial supporter of the conference and do not constitute an official part of that conference.

Copyright © 2008 Medscape.
Genentech, Forest Pharmaceuticals, Bristol-Myers Squibb, Abbott
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Recognize the limitations with current approaches to managing patients with systemic lupus erythematosus, Sjögren's syndrome, and gout
  2. Discuss the importance of new therapeutic approaches for inflammatory diseases, such as lupus nephritis, Sjögren's syndrome, and gout
  3. Review advances and novel therapies for the pharmacologic treatment of inflammatory diseases, including systemic lupus erythematosus, Sjögren's syndrome, and gout, and their relevance and potential application in clinical practice
Authors Disclosures

Doruk Erkan, MD
Disclosure: Doruk Erkan, MD, has disclosed that he has participated as a site investigator for Aspreva, Genentech, and Human Genome Sciences.


Robert I. Fox, MD, PhD
Disclosure: Robert I. Fox, MD, PhD, has disclosed that he has received grants for educational activities from and served as an advisor or consultant to Allergan, Biogen Idec, and Genentech.


Robert Terkeltaub, MD
Disclosure: Robert Terkeltaub, MD, has disclosed that he has received a grant for clinical research from TAP. Dr. Terkeltaub has also disclosed that he has served as a consultant for Regeneron, TAP, Savient, BioCryst, Novartis, and AR Scientific.


Helen Fosam
Disclosure: Helen Fosam, PhD, has disclosed no relevant financial relationships.


Jayashree Gokhale, PhD
Disclosure: Jayashree Gokhale, PhD, has disclosed no relevant financial relationships.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.